Solano Pineda Diana Laura, Marín Hernández Italia, Gómez Morales Luis, Nuñez Cruz Adolfo, Flores Peredo Vanesa, González Rubio Medina Erandi, Medina Quero Karen, Vargas Hernández Marco Antonio, Escalera Arroyo Pedro
Immunology Laboratory, Military School of Graduate Studies in Health, Secretariat of National Defense (SEDENA), Mexico City, MEX.
Medicine, Faculty of Higher Studies Iztacala, National Autonomous University of Mexico, (UNAM), Mexico City, MEX.
Cureus. 2025 Aug 12;17(8):e89937. doi: 10.7759/cureus.89937. eCollection 2025 Aug.
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in developing countries. The treatment of choice is intravitreal antiangiogenic therapy. However, there are discrepancies between outcomes observed in real-world clinical practice and those reported in clinical trials such as RIVAL, MARINA, ANCHOR, and PrONTO. Objective: The objective of this study was to explore real-world outcomes in visual acuity (VA) and central macular thickness (CMT) in patients with wet AMD treated with antiangiogenic therapy. Methods: This was an ambispective, observational, and analytical study. A total of 110 patients (132 eyes) diagnosed with wet AMD were included. All had complete clinical records, optical coherence tomography reports, and VA data from January 2017 to June 2020. Results: More than 80% of the eyes showed improvement in VA post-loading dose, along with a statistically significant reduction in CMT. The number of antiangiogenic injections ranged from 3 to 33, with an average follow-up of 20.8±12.5 months. Conclusion: Treatment received in real-world clinical practice differs from the protocols established in multicenter trials, particularly regarding injection frequency. Despite these variations, a positive trend was observed in both visual improvement and CMT reduction at the end of follow-up.
年龄相关性黄斑变性（AMD）是发展中国家不可逆性失明的主要原因之一。首选治疗方法是玻璃体内抗血管生成疗法。然而，在实际临床实践中观察到的结果与在RIVAL、MARINA、ANCHOR和PrONTO等临床试验中报告的结果存在差异。目的：本研究的目的是探讨接受抗血管生成疗法治疗的湿性AMD患者的视力（VA）和中心黄斑厚度（CMT）的实际治疗效果。方法：这是一项前瞻性、观察性和分析性研究。共纳入110例（132只眼）诊断为湿性AMD的患者。所有患者均有2017年1月至2020年6月完整的临床记录、光学相干断层扫描报告和VA数据。结果：超过80%的患眼在负荷剂量治疗后视力有所改善，同时CMT有统计学意义的降低。抗血管生成注射次数为3至33次，平均随访时间为20.8±12.5个月。结论：实际临床实践中的治疗与多中心试验制定的方案不同，特别是在注射频率方面。尽管存在这些差异，但在随访结束时，视力改善和CMT降低方面均观察到了积极趋势。
